- Home
- SEMR vs KROS Comparison
SEMR vs KROS Comparison
Compare SEMR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- KROS
- Stock Information
- Founded
- SEMR 2008
- KROS 2015
- Country
- SEMR United States
- KROS United States
- Employees
- SEMR N/A
- KROS N/A
- Industry
- SEMR EDP Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- KROS Health Care
- Exchange
- SEMR Nasdaq
- KROS Nasdaq
- Market Cap
- SEMR 1.1B
- KROS 565.0M
- IPO Year
- SEMR 2021
- KROS 2020
- Fundamental
- Price
- SEMR $7.38
- KROS $15.62
- Analyst Decision
- SEMR Buy
- KROS Buy
- Analyst Count
- SEMR 8
- KROS 14
- Target Price
- SEMR $14.88
- KROS $20.56
- AVG Volume (30 Days)
- SEMR 1.0M
- KROS 412.4K
- Earning Date
- SEMR 11-06-2025
- KROS 11-05-2025
- Dividend Yield
- SEMR N/A
- KROS N/A
- EPS Growth
- SEMR N/A
- KROS N/A
- EPS
- SEMR N/A
- KROS 0.47
- Revenue
- SEMR $413,962,000.00
- KROS $232,844,000.00
- Revenue This Year
- SEMR $20.28
- KROS $5,998.31
- Revenue Next Year
- SEMR $16.41
- KROS N/A
- P/E Ratio
- SEMR N/A
- KROS $33.74
- Revenue Growth
- SEMR 22.16
- KROS 85820.30
- 52 Week Low
- SEMR $7.01
- KROS $9.12
- 52 Week High
- SEMR $18.74
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- SEMR 40.02
- KROS 57.13
- Support Level
- SEMR $7.32
- KROS $15.34
- Resistance Level
- SEMR $7.90
- KROS $15.85
- Average True Range (ATR)
- SEMR 0.23
- KROS 0.45
- MACD
- SEMR 0.01
- KROS -0.02
- Stochastic Oscillator
- SEMR 9.15
- KROS 57.08
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.